Harpoon Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Harpoon Therapeutics has a total shareholder equity of $4.5M and total debt of $8.8M, which brings its debt-to-equity ratio to 194.4%. Its total assets and total liabilities are $47.6M and $43.0M respectively.
Key information
194.4%
Debt to equity ratio
US$8.83m
Debt
| Interest coverage ratio | n/a |
| Cash | US$31.61m |
| Equity | US$4.54m |
| Total liabilities | US$43.04m |
| Total assets | US$47.58m |
Recent financial health updates
Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely
Mar 11
Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation
Jul 30Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?
Mar 08Recent updates
Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified
Jan 30Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough
Oct 01Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts
Aug 14Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically
May 28Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely
Mar 11Harpoon Therapeutics appoints Luke Walker as CMO
Oct 04Harpoon Therapeutics: A Well Undervalued Tri-Specific Oncology Player
Sep 01Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation
Jul 30Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio
Jul 07Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?
Mar 08We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate
Nov 30Harpoon Therapeutics: A First Look
Sep 16Harpoon shares slide after early-stage prostate cancer study data fails to impress
Jun 04Financial Position Analysis
Short Term Liabilities: HARP's short term assets ($34.3M) exceed its short term liabilities ($18.1M).
Long Term Liabilities: HARP's short term assets ($34.3M) exceed its long term liabilities ($24.9M).
Debt to Equity History and Analysis
Debt Level: HARP has more cash than its total debt.
Reducing Debt: HARP's debt to equity ratio has increased from 0% to 194.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HARP has sufficient cash runway for 5 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: HARP is forecast to have sufficient cash runway for 11 months based on free cash flow estimates, but has since raised additional capital.